[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 646 participants.

Also called NCT01408303

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 646 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
  • Medpace, Inc. Registry lists this organization as a collaborator
Registry
  • NCT NCT01408303
Other papers using this trial's data
  • A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial) Clinical therapeutics, 2013-09 DOI, PubMed 23998969
  • Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial Lipids in health and disease, 2015-09-02 DOI, PubMed 26328624, PMC4557761 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01408303. Randomized; quadruple masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2012-06 (actual). Results posted on 2014-12-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
Acronym
ESPRIT
Condition
Hypertriglyceridemia
Condition
Cardiovascular Disease
Intervention (Drug)
Olive oil, 4g
Intervention (Drug)
omega-3-carboxylic acids, 2g
Intervention (Drug)
omega-3-carboxylic acids, 4g
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Omthera Pharmaceuticals, Inc (class: industry)
Collaborator
Medpace, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01408303
Content hash
701c305afb61578f57d4170f026f9901a0f51a6694e80fa463d8b7ef41c9258d